Sensorineural hearing loss in acromegalic patients under treatment  by Carvalho, Marcelo Alexandre et al.
98
Brazilian Journal of otorhinolaryngology 78 (4) July/august 2012
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Sensorineural hearing loss in acromegalic patients under treatment
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Acromegaly is a rare endocrine disease. Few studies have evaluated its association with hearing 
loss (HL) and the results are conflicting.
Aim: To evaluate the prevalence and features of HL in a group of patients being treated for acromegaly. 
To analyze peripheral and central auditory transmission.
Methods: Cross-sectional study. A group of 34 patients with acromegaly were submitted to metabolic 
evaluation, tonal audiometry and brainstem auditory evoked potentials. HL was considered when pure 
tone average was > 25 DBHL for low frequencies (250, 500, 1000 and 2000 Hz) or high frequencies 
(3000, 4000, 6000 and 8000 Hz). The patients were divided in group A (with HL) and B (without HL).
Results: Twelve patients (35.3%) had sensorineural HL (Group A), being 8 bilateral and 4 unilateral. 
No one had mixed or conductive HL. The prevalence of diabetes/impaired glucose tolerance was 
similar between the groups. The frequencies 3000, 4000, 6000 and 8000 Hz were the most affected 
and with a similar pattern in both ears.
Conclusion: sensorineural HL was found in 38.9% of cases. Neither clinical nor metabolic differences 
were noted between the groups, as well as in regards to peripheral and central auditory transmission.
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INTRODUCTION
Acromegaly is a rare endocrine disease, with an 
incidence of about five new cases per 1 million inhabitants 
every year1. Most of the cases are associated with a GH-
secreting pituitary adenoma; which induces the synthesis 
of the insulin-like-1 growth factor (IGF-1), which is the 
main mediator of GH metabolic and cellular proliferation 
actions1,2. The main comorbidities associated with acro-
megaly are: cardiovascular disease, diabetes, systemic 
blood hypertension, sleep apnea, arthritis and bone me-
tabolism disorders (osteoporosis)2-5. Among metabolic 
disorders, we may list carbohydrate metabolism disorders, 
such as diabetes mellitus , fasting glucose intolerance, 
insulin resistance, besides reduction in total cholesterol 
and increase in triglycerides3,5.
So far, very few studies have shown the involvement 
of peripheral nerves and acroparesthesia; nonetheless, 
without reports of changes to the central nervous systems, 
except for the compressive changes caused by pituitary 
tumors2,5,6. The involvement of hearing in acromegaly 
has been studied by numerous authors, with inconsistent 
results so far.
Maj et al.7 mentioned briefly a high incidence of 
conductive and mixed hearing loss in a group of 34 ac-
romegalic patients.
Menzel8 reported the case of a 72-year-old patient 
with bilateral sensorineural hearing loss with acromegaly, 
and such finding was associated to a temporal bone hyper-
trophy, with a resulting narrowing of the internal auditory 
meatuses, and pressure on the acoustic nerves.
In a study with 15 patients, Richards9 found con-
ductive hearing loss in five of the 30 ears investigated, 
associating this loss with otosclerosis, because in two cases 
they did unilateral exploratory tympanotomy, in which 
the stapes was fixed and was replaced by the prosthesis. 
In these cases, histopathological analysis of the footplates 
removed, showed active otosclerosis in one patient and 
inactive in another. Upon analyzing the auditory thresholds 
of the entire group and comparing it to a control popula-
tion, stated that there was sensorineural hearing loss in 
varied degrees in 100% of the patients. There was no sta-
tistically significant association between disease duration 
or circulating levels of GH, although the results seemed to 
indicate that the hearing thresholds were worse in those 
patients with lower GH circulating levels.
In a controlled study with 56 individuals with acro-
megaly referred to pituitary surgery, Doig & Gatehouse10, 
dis not find significant differences between the groups 
in relation to the auditory thresholds by bone and air 
conduction.
Crosara et al.11 held a controlled study with a group of 
15 patients (five men; 10 women; ages between 39-67 years) 
in which they used tonal audiometry, immittance measures 
and brainstem auditory evoked potentials (BAEP), and ra-
diological studies of the temporal bone. Results showed a 
high rate of abnormal results in all frequencies tested, espe-
cially at 4 and 8 KHz. Only one patient had mixed hearing 
loss. As to the BAEP, only 11 patients were assessed, and 
two had altered results. In both cases, wave I latency was 
normal in both sides, while in one patient there was an 
extension of the I-III interval, and in another, intervals I-
III and III-V were extended. The radiological assessment 
did not show changes to the middle ear, optical capsule or 
internal acoustic meatus. There was no correlation between 
the degree of hearing loss and GH levels.
Ozata et al.6 assessed the central and peripheral 
nervous systems using BAEP in acromegalic patients. More-
over, they assessed somatosensory evoked potentials of the 
tibial and median nerves in a group of 10 acromegalic pa-
tients (nine men, one woman, aged between 21-65 years) 
with untreated active disease (GH higher than 1 ng/mL), 
compared to 20 healthy controls. Patients with changes in 
the glucose tolerance test of hypothyroidism were taken 
off the study. Finally, they showed significant extension 
in the median and tibial nerve potentials; nonetheless, all 
BAEP components were normal. Thus, the results suggest 
that there is peripheral nerve involvement without central 
nerve involvement in patients assessed.
Babic et al.12 assessed a group of 30 untreated ac-
romegalic patients, compared to a group of 20 patients 
in searching for evidence of conductive hearing loss. 
There was a higher prevalence of middle ear ventilation 
problems in acromegalic patients, seven (23%), compared 
to none in the control group, p = 0.033. Such patients were 
significantly older, with a longer disease duration and 
lower medium levels of growth hormone in comparison 
to acromegalic patients without this problem.
Pilecki et al.13 held a study with 37 acromegalic 
(22 women, 15 men; mean age of 51.7 years, varying be-
tween 21.1-77.8 years) patients, compared to 47 healthy 
controls. They assessed peripheral nerve transmission, 
represented by the latency of the BAEP wave I, and the 
transmission at the level of the brainstem, represented 
by the I-V interpeak. In none of the cases they found 
alterations to the peripheral transmission. When the 74 
traces were analyzed, they found normal interpeak I-V 
latency results in 34 cases (45.9%), latency extension in 
33 cases (44.6%) and shortening in seven cases (9.5%). 
Such results suggested a non-homogeneous influence of 
acromegaly on brain function. The authors also suggested 
that the extension found in I-V intervals could suggest a 
reduction in the myelination of the auditory pathways of 
the brainstem, probably because of changes in glucose 
metabolism present in acromegalic patients. In the study, 
12 patients had active disease, while the others were in its 
inactive stage; however, they did not describe the treat-
ment success used to qualify these groups.
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Aydin et al.14 published recently the results 
from functional and structural assessment of hear-
ing in a group of 44 patients. Besides the audiometry 
and impedance measures, they also carried out MRI 
of the ear. The patients were further divided into 
three subgroups according to disease activity, fol-
lowing criteria from Giustina et al.15. The mean tonal 
thresholds (pure tone average-PTA) was determined 
based on the levels of air conduction in each ear, in 
the frequencies of 500; 1,000 and 2,000 KHz. PTA > 
15 dBHL was considered a hearing loss. Following 
such criterion, 21 patients (48%) had hearing loss in at 
least one ear. Moreover, four patients (9%) had conductive 
hearing loss, 13 (30%) sensorineural, and eight (18%) had 
mixed hearing loss in at least one of the affected sides. 
There were no differences between the subgroups as to 
hearing loss prevalence.
We can clearly see that the conclusions about HL in 
acromegalics are contradictory. The scarcity of studies and 
the limited number of patients are determining factors in 
these assessments. Thus, this paper aims at assessing the 
prevalence and possible factors associated with the HL in 
a group of patients with acromegaly in treatment, as well 
as checking the functioning of the peripheral and central 
hearing transmission in this group.
METHODS
We carried out a contemporary cohort study with a 
cross-sectional cutting in a specialized ward from a tertiary 
reference center. After approval by the Ethics Committee 
of the Institution (protocol # 065.08.07), the patients were 
assessed after signing the informed consent forms.
Sensorineural hearing loss (SNHL) was assessed by 
means of air and bone conduction pure tone audiometry 
with the Beltone 2000 - Clinical Audiometer (Eletronics 
corp.; Chicago, Ill.). HL was defined when the mean of 
the low/medium frequencies (250, 500, 1 and 2 KHz) or 
the mean in the high tones (3, 4, 6 and 8 KHz) was > 25 
dbHL in at least one ear.
Patients with past history of using ototoxic drugs, 
noise exposure, brain trauma or a past family history of 
hearing loss were taken off the study. We only included 
patients with strictly normal otoscopy. Only one patient 
had a unilateral tympanic perforation and was not included 
in the group. Two other patients were taken off, because 
the BAEPs were not possible to acquire because of elec-
trical interference of muscle activity. Two other patients 
with sensorineural HL were taken off for being 70 years 
old or older - because of the probable association with 
presbycusis.
Our final population was made up of 34 patients 
with acromegaly, 11 men (43.9 ± 6.2) and 23 women 
(48.7 ± 14.6).
Twelve patients (35.3%) had SNHL, while 22 
(64.7%) had normal auditory thresholds. The patients were 
broken down into two subgroups: group A with SNHL 
and group B without SNHL. No patient had conductive 
or mixed HL.
The groups were compared vis-à-vis clinical and 
laboratory parameters, including serum levels of growth 
hormone - GH and Insulin-like growth factor - 1 IGF-1. 
We considered the body mass index (BMI) high when 
greater than 25 Kg/m2.
We also grouped the patients as to the presence 
of active acromegaly. The patients were divided into two 
groups: with active disease and controlled disease. We 
defined controlled disease when the IGF-1 level was nor-
mal for gender and age and the GH level < 1.0 µg/litter, 
as per proposed by Giustina et al.4.
Moreover, all the patients were assessed by 
means of Brainstem Auditory Evoked Potentials (BEAP) 
with the Medical PC equipment, from Interacus-
tics A/S (Denmark, 2005) with the IaBaseII, version 
4.08 software, in a silent room. The potentials were 
evoked using 2000 thin clicks, with a stimulation rate 
of 20 clicks/second, with an intensity of 100 dBHL. The 
stimuli were monoaural (ABR-3A phone), with con-
tralateral masking (40 dBHL below the stimulus). The 
band-pass filter was kept between 0 and 3,000 Hz and 
impedance below 3 Kohms. We assessed the absolute 
latencies of waves I and the I-III, III-V and I-V interpeak 
intervals.
In order to assess the distribution normality, we 
used the Kolmogorov-Smirnov test, when necessary. We 
used the t-Student test to compare the mean values and 
the χ² to compare the ratios between groups, as well as 
the Fisher’s exact test. The results are presented as mean 
± standard deviation. We established a 5% significance 
level (α = 0.05). For the statistical analysis, we used the 
SPSS 12.0 Inc software.
RESULTS
Twelve (35.3%) patients had sensorineural HL 
(48.2 ± 9.0 years) - Group A; while 22 (64.7%) had 
normal hearing threshold (46.6 ± 14.3 years) - Group 
B. There was no difference vis-à-vis the age between 
the two groups (p = 0.7). Moreover, in both there were 
similar prevalences of diabetes/glucose intolerance (p 
= 1.5), 41.7% in Group A vs. 63.6% in group B. Group 
A had equal participation of both genders (six men: six 
women), while in Group B we found 17 women and five 
men.
Among the patients in Group A, eight had bilateral 
HL and four had unilateral. Moreover, four had HL for low 
and high frequency sounds, while eight had it in the high 
frequencies only (Table 1).
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The same happened with IGF-1 levels, when analyzed as 
continuous variable (Table 2). The mean estimated time 
of disease duration was 10.2 ± 5.5 years in Group A and 
7.7 ± 5.9 years in Group B, without significant differences 
between the groups (p = 0.2).
Table 1. Mean low and high frequency pure tone values in 
patients with SNHL (Group A) in the right and left ears.
Gender
Age 
(years)
Mean (250, 500, 1 
and 2 KHz) DBHL
Mean (3, 4, 6 and 
8 Khz) DBHL
RE LE RE LE
M 49 17.5 15 35 22.5
M 37 32.5 16.25 23.75 10
M 52 15 15 30 20
M 44 22.5 20 33.75 23.75
M 46 20 15 26.25 27.5
M 40 27.5 36.25 27.5 33.75
F 60 17.5 22.5 48.75 46.25
F 62 22.5 23.75 36.25 28.75
F 48 23.75 22.5 38.75 28.75
F 32 15 15 27.5 20
F 54 23.75 26.25 42.5 38.75
F 55 26.5 33.75 31.25 46.25
RE: right ear; LE: left ear.
When we analyzed each sound frequency alone, we 
found high auditory thresholds in both ears (> 25 DBHL) in 
almost all the frequencies analyzed in at least one patient. 
Such alteration prevailed in the frequencies of 3, 4, 6 and 
8 KHz bilaterally (Graphs 1 and 2).
Graph 1. Number of right ears with normal and altered tonal auditory 
thresholds (> 25 DBHL) in the different frequencies.
Graph 2. Number of left ears with normal and altered tonal auditory 
thresholds (> 25 DBHL) in the different frequencies.
Numerous laboratory data associated with metabo-
lism disorders were assessed in both groups. We assessed 
the levels of total cholesterol, HDL, LDL, triglycerides, 
fasting glucose, without significant differences between 
these parameters in Groups A and B (Table 2).
Group A patients had lower mean GH levels (mean 
= 1.76 µg/litter) vis-à-vis group B patients (mean = 4.4 µg/
litter), although without significant association (p = 0.2). 
Table 2. Biochemical parameters of patients with acromegaly 
in Groups A and B.
Group A Group B p-value
Glycemia (mg/dL) 96.5 ± 11.9 114.2 ± 28.6 0.5
Total cholesterol (mg/dL) 169.0 ± 49.2 169.4 ± 25.5 0.9
HDL (mg/dL) 44.5 ± 17.3 43.8 ± 11.9 0.8
LDL (mg/dL) 103.6 ± 34.6 92.3 ± 29.6 0.3
Triglycerides (mg/dL) 117.5 ± 79.7 134.1 ± 80.1 0.5
GH (μg/L) 1.7 ± 2.4 4.4 ± 7.3 0.2
IGF1 (ng/mL) 235.2 ± 278.4 313.2 ± 237.9 0.3
There was no statistically significant difference 
between the groups vis-à-vis the categorical variables: 
systemic arterial hypertension, transsphenoidal surgery, 
radiotherapy, use of cabergolin, normal IGF-1 level (titrated 
for gender and age range), normal or high BMI. When the 
groups were analyzed in relation to active acromegaly and 
hearing loss, there was no statistical association (p = 0.4)
When we assessed the wave I absolute latencies and 
the I-III, III-V and I-V interpeak intervals for the right and 
left ears, separately, there were no significant differences 
between Groups A and B (Tables 3 and 4).
Table 3. Latencies of the brainstem auditory evoked potentials 
in the right ears of Groups A and B.
BAEP (ms) Group A Group B p-value
Wave I 1.51 ± 0.25 1.39 ± 0.26 0.1
I-III Interval 2.12 ± 0.33 2.27 ± 0.28 0.2
III-V Interval 2.02 ± 0.39 1.91 ± 0.25 0.3
I-V Interval 4.14 ± 0.36 4.19 ± 0.36 0.7
Table 4. Latencies of the brainstem auditory evoked potentials 
in the left ears of Groups A and B.
BAEP (ms) Group A Group B p-value
Wave I 1.40 ± 0.20 1.32 ± 0.25 0.3
I-III Interval 2.24 ± 0.33 2.29 ± 0.38 0.6
III-V Interval 1.98 ± 0.28 1.87 ± 0.37 0.4
I-V Interval 4.22 ± 0.31 4.17 ± 0.34 0.7
DISCUSSION
There are very few papers in the literature discuss-
ing the possible association between hearing loss and 
acromegaly. In the present study, there was a prevalence 
of 14 patients (38.9%) with sensorineural hearing loss, 
mainly bilateral and in the high frequencies (Table 1). 
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Aydin et al.14 found a HL prevalence of 48%; 30% senso-
rineural; however, they used PTA > 15 DBHL as criterion, 
more sensitive than what was used in the present study.
There were no patients with conductive or mixed 
HL in the group assessed. Thus, such results did not re-
inforce what was proposed by Richards9 about the higher 
incidence of otosclerosis in acromegaly, when it is expected 
to have conductive HL with a normal tympanic membrane.
When we assessed each frequency alone in both 
ears (Graphs 1 and 2) we also noticed the presence of 
increased auditory thresholds. Altered results were present 
in almost all frequencies assessed, at least in one patient. 
Moreover, they predominated in the high frequency sounds 
and bilaterally. Such results are similar to those reported by 
Crosara et al.11, who reported high rates of altered results, 
especially at 4 and 8 KHz.
Upon comparing Groups A and B, it was not pos-
sible to identify significant associations between medications 
being used, comorbidities and metabolism disorders with 
SNHL. We stress that Group A patients had higher mean age, 
longer disease durations and lower GH levels than those in 
Group B; however, without statistical significance. Similarly, 
Richards9 concluded that their results seemed to indicate that 
the hearing thresholds were worse in those patients with 
lower levels of circulating GH. Contrary to that, Babic et al.12 
found similar changes (older age, longer disease duration 
and lower GH levels) when they compared patients with 
acromegaly with and without middle ear ventilation disor-
der; in this case, the changes were statistically significant.
The proportion of patients with active acromegaly, 
according to criteria from Giustina et al.4, was similar in 
both groups. Thus, there seems not to be, at least directly, 
negative interference of the excessive levels of GH and 
IGF-1 on the functioning of the peripheral auditory system, 
at a cochlear or retrocochlear level.
The present study may have been the first to do the 
comparison model of the BAEP among acromegalic patients 
with and without SNHL. When we assessed the transmission 
of auditory electrical impulses by means of BAEP, we found 
no significant differences between Groups A and B. All the 
patients were submitted to checking tonal auditory thresholds 
and had thresholds which enabled acquiring the potentials.
Thus, even with altered auditory thresholds in dif-
ferent frequencies in Group A, there was no difference 
between the groups in the neural transmission at the level 
of the auditory nerve (wave I) and the brainstem (I-III and 
III-V interpeak interval).
In our study, we could not determine the factors 
which could be involved in HL development in patients 
with acromegaly. Associated and prevalent factors in this 
disease, such as diabetes/fasting glucose intolerance, sys-
temic arterial hypertension and high body mass index were 
not statistically associated to the outcome. Lower GH levels, 
longer disease duration and higher mean age may be associ-
ated to the sensorineural HL, but require a larger number of 
studies and larger groups of individuals for a better statistical 
analysis. Because of this disease rarity, we cannot expect to 
have studies with larger groups of individuals.
Issues as to the real cause-and-effect relationship 
between acromegaly and HL require longitudinal studies, 
in which the causal factors may be assessed with greater 
accuracy. Cross-sectional studies may reveal statistical as-
sociations, however, without determining causality.
CONCLUSION
In the present study, we found a SNHL prevalence 
of 35.3% in a group of patients with acromegaly being 
treated. There was a predominance of bilateral losses and 
in the high frequencies. The most affected frequencies 
were 3,000; 4,000; 6,000 and 8,000 Hz, in both ears.
There was no statistical relation between SNHL and 
the clinical-laboratory parameters analyzed, including disease 
duration, mean age, disease activity, metabolical disorders, 
GH and IGF-1 levels. Moreover, there were no peripheral 
transmission disorder or at the level of the brainstem on the 
auditory pathways, when Groups A and B were compared.
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